Amirali Talasaz Buys Shares of Guardant Health

Amirali Talasaz, Co-Chief Executive Officer of Guardant Health, Inc. (NasdaqGS:GH), purchased 111,804 shares of the company on June 26, 2026. The transaction was valued at approximately $467,340.72, with an average price of $4.18 per share.

Insider Buying and Selling at Guardant Health, Inc.

Amirali Talasaz, Co-CEO of Guardant Health, was active in the stock market recently. On June 26, 2026, he bought 111,804 shares at an average price of $4.18, totaling around $467,340.72. This transaction was not part of a pre-planned trading program. Additionally, on June 29, 2026, Talasaz executed several transactions, including both planned and unplanned sales, at varying prices.

Other Institutional Activity in Guardant Health

Institutional investors have shown varied interest in Guardant Health. BlackRock, Inc. increased its holdings by 236,045 shares, bringing its total to 11,553,759 shares worth about $1.07 billion, a 2.1% increase. Price T Rowe Associates added 1,387,611 shares, ending with 7,023,689 shares valued at approximately $648.78 million, marking a 24.6% increase. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, with 5,837,992 and 5,624,180 shares, respectively. Meanwhile, Invesco Ltd. reduced its stake by 369,465 shares, resulting in a 7.0% decrease, ending with 4,946,469 shares valued at $456.91 million.

Guardant Health, Inc. Stock Down 5.7%

Shares of Guardant Health traded near $153.74 on Wednesday. The company has a market cap of $19.79 billion. Although it has no meaningful P/E ratio due to ongoing losses, its beta is 1.619, indicating higher volatility compared to the market. The stock's 52-week range is between $40.35 and $151.85, with a 50-day moving average of $111.18 and a 200-day moving average of $95.82.

Recent Earnings

Guardant Health reported revenue of approximately $1.08 billion, with a growth rate of 48.3%. However, the company is not currently profitable, with a net margin of -40.1%. Its next earnings report is expected on July 29, 2026.

Analysts Set New Price Targets

Analysts remain optimistic about Guardant Health's prospects. On June 29, 2026, Guggenheim maintained its 'buy' rating with a $160 price target. Bernstein reinstated its 'buy' rating on June 26, 2026, setting a target of $175. Barclays, RBC Capital, and others also have 'buy' ratings, with targets ranging up to $185. The consensus recommendation is a 'strong buy', with an average target price of $144.42 based on 24 analyst opinions.

About Guardant Health, Inc.

Guardant Health, Inc. is a healthcare company specializing in precision oncology. Based in Palo Alto, California, it offers a range of blood and tissue tests for cancer detection and profiling. Its flagship products include the Guardant360 CDx test and the Guardant Reveal test. The company, led by CEO Dr. Helmy Eltoukhy, employs approximately 2,490 people and collaborates with Nuvalent, Inc. in oncology drug development.

Bottom Line

Amirali Talasaz's recent purchase of Guardant Health shares highlights insider confidence in the company's future. Investors often track such insider transactions as potential indicators of a company's prospects. However, it's important to remember that these trades are disclosed after the fact and may not reflect current positions.